Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
L FehrenbacherFabrice Barlesi

Abstract

The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second- or third-line treatment in patients with advanced NSCLC in the primary (n = 850) and secondary (n = 1225) efficacy populations of the randomized phase III OAK study (respectively referred to as the intention-to-treat [ITT] 850 [ITT850] and ITT1225) at an updated data cutoff were assessed. Patients received atezolizumab, 1200 mg, or docetaxel, 75 mg/m2, intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively. The primary end point was overall survival (OS) in the ITT population and programmed death-ligand 1-expressing subgroup. A sensitivity analysis was conducted to evaluate the impact of subsequent immunotherapy use in the docetaxel arm on the observed survival benefit with atezolizumab. Atezolizumab demonstrated an OS benefit versus docetaxel in the updated ITT850 (hazard ratio [HR] = 0.75, 95% confidence interval: 0.64-0.89, p = 0.0006) and the ITT1225 (HR = 0.80, 95% confidence interval: 0.70-0.92, p = 0.0012) after minimum follow-up times of 26 and 21 months, respectively. Improved survival with atezolizumab was observed across programmed death-ligand 1 and histological subgroups. In the im...Continue Reading

Citations

May 9, 2019·Future Oncology·Martin ReckKenneth J O'Byrne
May 31, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VansteenkisteD De Ruysscher
Feb 18, 2020·Expert Review of Molecular Diagnostics·Rumiko Shimazawa, Masayuki Ikeda
Mar 21, 2020·JCO Oncology Practice·Omer Ben-AharonDaniel A Goldstein
May 19, 2020·American Society of Clinical Oncology Educational Book·Antonio CallesJulie R Brahmer
Aug 3, 2019·Medicines·Purushottam LamichhaneNarottam Lamichhane
Sep 3, 2018·Virchows Archiv : an International Journal of Pathology·Spasenija Savic Prince, Lukas Bubendorf
Feb 6, 2020·Nature Genetics·Jianbin ChenWeiwei Zhai
Jan 18, 2020·Journal of Cancer Survivorship : Research and Practice·Rebekah ParkJacob McAuliffe
Aug 18, 2020·OncoTargets and Therapy·Wei LiuJianhui Cai
Jul 31, 2020·World Journal of Clinical Oncology·Fillipe Dantas PinheiroFabrício Freire de Melo
Jul 2, 2019·Frontiers in Immunology·Xiangfeng ShenZhi-Xiang Xu
Jul 31, 2020·Therapeutic Advances in Medical Oncology·Bin ZhaoJiaxin Zhao
Aug 9, 2020·OncoTargets and Therapy·Sneha GullapalliGilberto Lopes
Aug 25, 2020·The British Journal of Ophthalmology·Blake Hugo FortesLauren A Dalvin
Jan 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mattia BoeriGabriella Sozzi
Apr 15, 2020·Cancer Cell·Adam J Schoenfeld, Matthew D Hellmann
Dec 25, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sylvie LantuejoulMari Mino-Kenudson
Jan 14, 2021·Survey of Ophthalmology·Carmen Alba-Linero, Emilio Alba
Feb 25, 2021·Pharmacogenomics and Personalized Medicine·Juliana Machado-RugoloVera Luiza Capelozzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.